Cellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021.